MENTICE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.1 SEK | -0.82% |
|
+0.28% | -24.32% |
| 04-02 | Mentice Receives an Order of USD 795,000 for Development Services from A World-Leading Medtech Company | CI |
| 03-21 | Transcript : Mentice AB - Analyst/Investor Day |
| Sales 2024 * | 335M 30.8M 2.46B | Sales 2025 * | 412M 37.84M 3.02B | Capitalization | 923M 84.76M 6.76B |
|---|---|---|---|---|---|
| Net income 2024 * | 20M 1.84M 146M | Net income 2025 * | 40M 3.67M 293M | EV / Sales 2024 * | 2.52 x |
| Net cash position 2024 * | 79.05M 7.26M 579M | Net cash position 2025 * | 112M 10.25M 818M | EV / Sales 2025 * | 1.97 x |
| P/E ratio 2024 * |
46.3
x | P/E ratio 2025 * |
22.5
x | Employees | 114 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mentice AB
| 1 day | -0.82% | ||
| 1 week | +0.28% | ||
| Current month | +8.41% | ||
| 1 month | +8.41% | ||
| 3 months | -27.07% | ||
| 6 months | +24.48% | ||
| Current year | -24.32% |
1 week
36.10
38.60
1 month
32.0038.60
Current year
30.1071.40
1 year
25.1071.40
3 years
25.10185.00
5 years
25.10185.00
10 years
25.10185.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 31/12/98 | |
| Chief Executive Officer | 76 | 31/12/07 | |
Jonatan Sjostrom
COO | Chief Operating Officer | - | 13/09/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 31/12/07 | |
Magnus Nilsson
CHM | Chairman | 68 | 26/04/22 |
| Director/Board Member | 71 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 36.1 | -0.82% | 377 |
| 25/04/24 | 36.4 | -0.82% | 9,682 |
| 24/04/24 | 36.7 | -3.93% | 3,848 |
| 23/04/24 | 38.2 | +7.61% | 7,961 |
| 22/04/24 | 35.5 | -1.39% | 2,099 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 12:46 pm
More quotes
Mentice AB is a Sweden-based medical technology company. It provides software and hardware simulation solutions and related services for endovascular therapies. The Companyâs solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Companyâs solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The Company also covers neurovascular, cardiovascular and peripheral interventions, among others. It is active globally.
Calendar
03/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
36.1
SEK
Average target price
55.33
SEK
Spread / Average Target
+53.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.32% | 84.19M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.07B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- MNTC Stock
